The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute
Ottawa's academic cancer centre, a world leader in oncolytic viruses (John Bell), the first made-in-Canada CAR-T trial and pragmatic REaCT trials.
The Ottawa Hospital Cancer Centre and the Ottawa Hospital Research Institute (OHRI) form eastern Ontario's academic cancer programme with the University of Ottawa. John Bell's laboratory is one of the world's leading oncolytic virus groups, developing the Maraba MG1 and vaccinia platforms and co-founding Turnstone Biologics; Rebecca Auer studies perioperative immunotherapy to prevent metastasis after surgery. Natasha Kekre led CLIC-01, the first clinical trial of a CAR-T product manufactured in Canada, and the Rethinking Clinical Trials (REaCT) programme, led by Mark Clemons and Dean Fergusson, embeds pragmatic randomised trials into routine cancer care. The centre also hosts a large radiation oncology and haematology service.
- Oncolytic viruses
- Made-in-Canada CAR-T (CLIC-01)
- Pragmatic trials (REaCT)
- Perioperative immunotherapy
Pages like this
not linked directly; found by shared links- InstitutionCancer Care Alberta (Alberta Health Services)
Shares Canadian Cancer Trials Group (CCTG), Oncolytic viruses, Real-world evidence, HR-positive / HER2-negative breast cancer.
- IdeaPre-consented cohorts that can be randomised to future trials (TwiCs)
Shares Trials enrol too few, too slowly, Trial design, endpoints and cost, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaPoint-of-care randomisation built into the oncology record
Shares Trials enrol too few, too slowly, Real-world evidence, Trial design, endpoints and cost.
- InstitutionJuravinski Cancer Centre / Escarpment Cancer Research Institute
Shares Canadian Cancer Trials Group (CCTG), Trial design, endpoints and cost, CAR-T cell therapy, HR-positive / HER2-negative breast cancer.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaRegistry-based randomised trials for oncology comparative effectiveness
Shares Trials enrol too few, too slowly, Real-world evidence, Trial design, endpoints and cost.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.